Lee S Simon

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi request reprint A Food and Drug Administration primer
    Lee S Simon
    Harvard Medical School, Beth Israel Deaconess Medical Center, 110 Francis Street 4B, Boston, MA 02115, USA
    Arthritis Rheum 55:4-8. 2006
  2. ncbi request reprint Osteoporosis
    Lee S Simon
    Harvard Medical School, Beth Israel Deaconess Hospital, 330 Brookline Avenue, Boston, MA 02215, USA
    Rheum Dis Clin North Am 33:149-76. 2007
  3. pmc Patients, their doctors, nonsteroidal anti-inflammatory drugs and the perception of risk
    Lawrence Goldkind
    Department of Gastroenterology, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
    Arthritis Res Ther 8:105. 2006
  4. ncbi request reprint Is milnacipran effective in treating pain in patients with fibromyalgia?
    Lee S Simon
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Nat Clin Pract Rheumatol 2:126-7. 2006
  5. ncbi request reprint The COX 2 selective inhibitors: what the newspapers have not told you
    Lee S Simon
    Harvard Medical School, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Bull NYU Hosp Jt Dis 65:229-41. 2007
  6. ncbi request reprint Preliminary development of a responder index for chronic low back pain
    Lee S Simon
    Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02465, USA
    J Rheumatol 34:1386-91. 2007
  7. ncbi request reprint The COX-2 inhibitors: a reasoned review of the data
    Lee S Simon
    Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Swiss Med Wkly 135:419-24. 2005
  8. ncbi request reprint A world without Vioxx: to COX-2 or not to COX-2?
    Lee S Simon
    Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA, USA
    Cleve Clin J Med 71:849-50, 852, 854 passim. 2004
  9. ncbi request reprint The treatment of rheumatoid arthritis
    Lee S Simon
    Beth Israel Deaconess Medical Center, Harvard Medical School, 110 Francis St Suite 4B, Boston, MA 02215, USA
    Best Pract Res Clin Rheumatol 18:507-38. 2004
  10. doi request reprint How to ascertain drug safety in the context of benefit. Controversies and concerns
    Lee S Simon
    Harvard Medical School, Boston, MA, USA
    J Rheumatol 36:2114-21. 2009

Collaborators

Detail Information

Publications28

  1. ncbi request reprint A Food and Drug Administration primer
    Lee S Simon
    Harvard Medical School, Beth Israel Deaconess Medical Center, 110 Francis Street 4B, Boston, MA 02115, USA
    Arthritis Rheum 55:4-8. 2006
  2. ncbi request reprint Osteoporosis
    Lee S Simon
    Harvard Medical School, Beth Israel Deaconess Hospital, 330 Brookline Avenue, Boston, MA 02215, USA
    Rheum Dis Clin North Am 33:149-76. 2007
    ..Effective therapies are available for the patient who has arthritic osteoporosis. The approach is critical to ensure an optimal quality of life in these individuals who suffer with a disease that is clearly treatable...
  3. pmc Patients, their doctors, nonsteroidal anti-inflammatory drugs and the perception of risk
    Lawrence Goldkind
    Department of Gastroenterology, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
    Arthritis Res Ther 8:105. 2006
    ....
  4. ncbi request reprint Is milnacipran effective in treating pain in patients with fibromyalgia?
    Lee S Simon
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Nat Clin Pract Rheumatol 2:126-7. 2006
  5. ncbi request reprint The COX 2 selective inhibitors: what the newspapers have not told you
    Lee S Simon
    Harvard Medical School, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Bull NYU Hosp Jt Dis 65:229-41. 2007
  6. ncbi request reprint Preliminary development of a responder index for chronic low back pain
    Lee S Simon
    Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02465, USA
    J Rheumatol 34:1386-91. 2007
    ..The aim of the OMERACT Special Interest Group was to discuss the development and validation of a preliminary responder index in CLBP...
  7. ncbi request reprint The COX-2 inhibitors: a reasoned review of the data
    Lee S Simon
    Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Swiss Med Wkly 135:419-24. 2005
    ....
  8. ncbi request reprint A world without Vioxx: to COX-2 or not to COX-2?
    Lee S Simon
    Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA, USA
    Cleve Clin J Med 71:849-50, 852, 854 passim. 2004
  9. ncbi request reprint The treatment of rheumatoid arthritis
    Lee S Simon
    Beth Israel Deaconess Medical Center, Harvard Medical School, 110 Francis St Suite 4B, Boston, MA 02215, USA
    Best Pract Res Clin Rheumatol 18:507-38. 2004
    ....
  10. doi request reprint How to ascertain drug safety in the context of benefit. Controversies and concerns
    Lee S Simon
    Harvard Medical School, Boston, MA, USA
    J Rheumatol 36:2114-21. 2009
    ..Each attendee spoke on a given topic and the group was charged to consider the issue of risk in the context of formally posed questions. This article provides a summary of the presentations and outlines the discussions that followed...
  11. ncbi request reprint Osteoporosis
    Lee S Simon
    Harvard Medical School, Beth Isreal Deaconess Hospital, 330 Brookline Avenue, Boston, MA 02215, USA
    Clin Geriatr Med 21:603-29, viii. 2005
    ..Newer therapies such as parathyroid hormone may improve the fracture risk even more than biphosphonates over a shorter period of time...
  12. ncbi request reprint Analysis of aspirin-associated risks in healthy individuals
    Chin Hur
    Harvard Medical School, Institute for Technology Assessment and Gastrointestinal Unit, Massachusetts General Hospital, Boston, MA 02114 4719, USA
    Ann Pharmacother 39:51-7. 2005
    ..Aspirin therapy is widely accepted for patients with documented cardiovascular disease, but there is a growing trend among healthy individuals to use aspirin as primary prevention for both cardiovascular disease and cancer...
  13. ncbi request reprint The cost-effectiveness of aspirin versus cyclooxygenase-2-selective inhibitors for colorectal carcinoma chemoprevention in healthy individuals
    Chin Hur
    Institute for Technology Assessment, Massachusetts General Hospital, 101 Merrimac Street, 10th Floor, Boston, MA 02114, USA
    Cancer 101:189-97. 2004
    ..Accruing evidence suggests that cyclooxygenase-2-selective inhibitors (coxibs) may be effective for colorectal carcinoma (CRC) chemoprevention but would not provide the primary cardiac benefit of aspirin...
  14. ncbi request reprint Controversies in COX-2 selective inhibition
    Lee S Simon
    Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    J Rheumatol 29:1501-10. 2002
  15. ncbi request reprint Perception of risk: the state of COX-2 selective inhibitors
    Lee S Simon
    Harvard Medical School, Beth Israel Deaconess Medical Center, 110 Francis Street, Suite 5A, Boston, MA 02115, USA
    Curr Rheumatol Rep 7:163-6. 2005
  16. doi request reprint Efficacy and safety of topical diclofenac containing dimethyl sulfoxide (DMSO) compared with those of topical placebo, DMSO vehicle and oral diclofenac for knee osteoarthritis
    Lee S Simon
    SDG LLC Consulting, 124 Mt Auburn Street, Cambridge, MA, USA
    Pain 143:238-45. 2009
    ..TDiclo in DMSO vehicle is an effective treatment option for knee osteoarthritis with efficacy similar to, but tolerability better than ODiclo. DMSO vehicle was no more efficacious than placebo...
  17. doi request reprint Observations from the OMERACT Drug Safety Summit, May 2008
    Lee S Simon
    Harvard Medical School, Boston, MA, USA
    J Rheumatol 36:2110-3. 2009
    ..At the Drug Safety Summit held at OMERACT 9, specialists spoke on their given topics and the group considered risk in the context of formally posed questions...
  18. pmc American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials
    David T Felson
    Boston University School of Medicine, Boston, Massachusetts, USA
    Arthritis Rheum 63:573-86. 2011
    ..This work was undertaken to develop such a definition...
  19. doi request reprint Patient-reported outcomes in chronic gout: a report from OMERACT 10
    Jasvinder A Singh
    Medicine Service, Birmingham Veterans Affairs VA Medical Center and Division of Rheumatology, Department of Medicine, University of Alabama, Birmingham, AL 35294, USA
    J Rheumatol 38:1452-7. 2011
    ..To summarize the endorsement of measures of patient-reported outcome (PRO) domains in chronic gout at the 2010 Outcome Measures in Rheumatology Meeting (OMERACT 10)...
  20. ncbi request reprint Cardiovascular effects of selective COX-2 inhibition: is there a class effect? The International COX-2 Study Group
    Leslie J Crofford
    Center for the Advancement of Women s Health, University of Kentucky, Lexington, Kentucky, USA
    J Rheumatol 33:1403-8. 2006
    ....
  21. ncbi request reprint Chronic pain and fibromyalgia: the regulatory perspective
    James Witter
    Division of Anti inflammatory, Analgesic and Ophthalmic Drug Products, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD, USA
    Best Pract Res Clin Rheumatol 17:541-6. 2003
    ..It will also begin to familiarize the reader with the importance of the so-called 'label' and some of its roles to enable the best 'risk-benefit' decisions be made for, and by, patients with chronic pain...
  22. ncbi request reprint The use of rheumatoid arthritis health-related quality of life patient questionnaires in clinical practice: lessons learned
    Simcha M Russak
    Zynx Health Incorporated, Beverly Hills, California, USA
    Arthritis Rheum 49:574-84. 2003
    ....
  23. ncbi request reprint The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus
    James R Sowers
    State University of New York, Brooklyn, USA
    Arch Intern Med 165:161-8. 2005
    ..Therefore, we conducted a double-blind, randomized trial to evaluate the effects of celecoxib, rofecoxib, and naproxen on 24-hour blood pressure (BP) in patients with type 2 diabetes, hypertension, and osteoarthritis...
  24. pmc Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance
    Jeffrey S Borer
    The Howard Gilman Institute for Valvular Heart Diseases at Weill Medical College of Cornell University, New York, New York, USA
    Arthritis Res Ther 7:S14-22. 2005
    ....
  25. ncbi request reprint Minimal disease activity for rheumatoid arthritis: a preliminary definition
    George A Wells
    Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Ontario, Canada
    J Rheumatol 32:2016-24. 2005
    ..This set of 2 definitions gained approval of 73% of the attendees. These (and other) definitions will now be subject to further validation in other databases...
  26. ncbi request reprint Fibromyalgia syndrome
    Philip J Mease
    Swedish Medical Center, The University of Washington School of Medicine, Seattle, WA, USA
    J Rheumatol 32:2270-7. 2005
    ..A prioritized list of domains of FM to be investigated was thus developed, key issues and controversies in the field were debated, and consensus on a research agenda on outcome measure development was reached...
  27. ncbi request reprint Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis st
    Clifton O Bingham
    Division of Rheumatology, Johns Hopkins University, 5200 Eastern Avenue, Mason F Lord Building, Center Tower, Room 404, Baltimore, MD 21224, USA
    Arthritis Rheum 54:3494-507. 2006
    ....
  28. ncbi request reprint Hyperbole, innuendo, and fact: the strange case of COX-2 selective inhibitors
    Lee S Simon
    J Rheumatol 33:1-3. 2006